Rabbit Polyclonal CYP2A6V2 Antibody

CYP2A6V2. a variant of the cytochrome P450 2A6 enzyme, is primarily involved in metabolizing xenobiotics, including nicotine, certain drugs (e.g., tegafur), and environmental toxins. The CYP2A6 gene exhibits genetic polymorphisms, with CYP2A6V2 (also designated as *2) representing a well-characterized allelic variant. This variant arises from a gene conversion event between CYP2A6 and the homologous pseudogene CYP2A7. resulting in amino acid substitutions (e.g., Arg128Leu) that alter enzyme activity. Individuals carrying CYP2A6V2 often exhibit reduced metabolic capacity, influencing nicotine dependence susceptibility and drug response variability. Antibodies targeting CYP2A6V2 are critical tools for studying its expression, localization, and functional impact in tissues like the liver and respiratory tract. These antibodies enable detection of protein levels in clinical samples, aiding research on interindividual metabolic differences, personalized medicine, and disease associations (e.g., smoking-related cancers). Specificity validation is essential due to high homology among CYP2A subfamily members. Current applications include immunohistochemistry, Western blotting, and enzyme activity inhibition studies, contributing to pharmacogenomics and toxicology research.